Chai Discovery Collaborates with Bristol Myers Squibb to Advance AI-Driven Antibody Discovery
Chai Discovery and Bristol Myers Squibb partner to advance Artificial Intelligence (AI)-driven antibody discovery, leveraging Chai’s molecular folding and design models to identify antibody candidates.
Computational Drug Discovery | 21/08/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy